 The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen FEC 100 - TAXOTERE - HERCEPTIN - PERTUZUMAB and a non anthracycline-based regimen TAXOTERE - CARBOPLATINE - HERCEPTIN - PERTUZUMAB according to the presence or not of TOP2A gene amplification in a population of breast cancer patients with HER2 overexpression. 